APA

Axelson M., Liu K., Jiang X., He K., Wang J., Zhao H., Kufrin D., Palmby T., Dong Z., Russell A. M., Miksinski S., Keegan P. & Pazdur R. (20131112). U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Axelson Michael, Liu Ke, Jiang Xiaoping, He Kun, Wang Jian, Zhao Hong, Kufrin Dubravka, Palmby Todd, Dong Zedong, Russell Anne Marie, Miksinski Sarah, Keegan Patricia and Pazdur Richard. 20131112. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Axelson M., Liu K., Jiang X., He K., Wang J., Zhao H., Kufrin D., Palmby T., Dong Z., Russell A. M., Miksinski S., Keegan P. and Pazdur R. (20131112). U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Axelson Michael, Liu Ke, Jiang Xiaoping, He Kun, Wang Jian, Zhao Hong, Kufrin Dubravka, Palmby Todd, Dong Zedong, Russell Anne Marie, Miksinski Sarah, Keegan Patricia and Pazdur Richard. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20131112.